Dr. Hirotoshi Watanabe (Kyoto University Graduate School of Medicine, JP) discusses the results of the STOPDAPT-2 ACT study. The aim of this study was to assess the safety of reducing dual antiplatelet therapy (DAPT) duration to 1-month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute coronary syndrome (ACS).
The trial showed that in ACS patients who underwent successful PCI using CoCr-EES, clopidogrel monotherapy after 1-month DAPT failed to attest the noninferiority to 12-month DAPT with aspirin and clopidogrel for the net clinical benefit with a trend toward increase in cardiovascular events despite reduction in major bleeding events.
Importance of the study
Key methods and results
Impact on practice
Applicability to populations outside of Japan
Recorded remotely from Tokyo, 2021.
Editor: Mirjam Boros